Abstract
The use of oral contraceptives first became widespread some 40 years ago, and reports of an excess risk of cardiovascular disease among women who used these agents soon followed. Few drugs have been the object of such intensive epidemiological research, the outcome of which has provided clinicians with detailed information about risks not only of specific thrombotic diseases but also important non-contraceptive benefits from the pill. Recently, oral contraceptives have been classified by some according to “generation” (first, second, third, and most recently, fourth generation): first-generation formulations containing lynestrenol or norethindrone, secondgeneration formulations containing levonorgestrel, third-generation formulations containing desogestrel or gestodene, and oral contraceptives containing an estrogen and other progestagens (cyproterone or norgestimate) or a progestagen alone. The results of several studies was that the use of the older high-dose oral contraceptives increased the risk of cardiovascular disease by modifying the Low-density lipoprotein and High-Density lipoprotein cholesterol level, increasing triglyceride serum level, reducing glucose tolerance, raising blood pressure, and promoting clotting mechanisms. In this review we investigate the mechanism of the oral contraceptives and performed a risk assessment of every generation.
Keywords: Oral contraceptives, cardiovascular risk, generation, levonogestren, gestodene, desogestrel, Protrhombotic Effects, Contraceptives, cardiovascular dis-ease, thrombotic diseases, lynestrenol, norethindrone, levonorgestrel, estrogen, progestagens, cyproterone, norgestimate, progestagen alone, High-Density lipoprotein, triglyceride serum level, glucose tolerance, blood pressure, clotting mechanisms, cardial infarction, pulmonary embolism, venous thrombosis, atherosclerosis, sex hormones, monophasic gestodene, preparation, HDL, nandrolone derivatives, medroxyprogesterone acetate, diabetes mellitus, insulin, diuretics, antisympathetic agents, an-timineralocorticoid effect, fibrinolytic pathways, prothrombin, factor VII, factor VIII, factor X, fibrinogen, dislypidemia, coronary thrombosis, coronary heart disease
Current Pharmaceutical Design
Title: Protrhombotic Effects of Contraceptives
Volume: 16 Issue: 31
Author(s): Giovanni Fazio, Filippo Ferrara, Giuseppe Barbaro Gullotti Alessandro, Giovanni Ferrro, Giuseppina Novo and Salvatore Novo
Affiliation:
Keywords: Oral contraceptives, cardiovascular risk, generation, levonogestren, gestodene, desogestrel, Protrhombotic Effects, Contraceptives, cardiovascular dis-ease, thrombotic diseases, lynestrenol, norethindrone, levonorgestrel, estrogen, progestagens, cyproterone, norgestimate, progestagen alone, High-Density lipoprotein, triglyceride serum level, glucose tolerance, blood pressure, clotting mechanisms, cardial infarction, pulmonary embolism, venous thrombosis, atherosclerosis, sex hormones, monophasic gestodene, preparation, HDL, nandrolone derivatives, medroxyprogesterone acetate, diabetes mellitus, insulin, diuretics, antisympathetic agents, an-timineralocorticoid effect, fibrinolytic pathways, prothrombin, factor VII, factor VIII, factor X, fibrinogen, dislypidemia, coronary thrombosis, coronary heart disease
Abstract: The use of oral contraceptives first became widespread some 40 years ago, and reports of an excess risk of cardiovascular disease among women who used these agents soon followed. Few drugs have been the object of such intensive epidemiological research, the outcome of which has provided clinicians with detailed information about risks not only of specific thrombotic diseases but also important non-contraceptive benefits from the pill. Recently, oral contraceptives have been classified by some according to “generation” (first, second, third, and most recently, fourth generation): first-generation formulations containing lynestrenol or norethindrone, secondgeneration formulations containing levonorgestrel, third-generation formulations containing desogestrel or gestodene, and oral contraceptives containing an estrogen and other progestagens (cyproterone or norgestimate) or a progestagen alone. The results of several studies was that the use of the older high-dose oral contraceptives increased the risk of cardiovascular disease by modifying the Low-density lipoprotein and High-Density lipoprotein cholesterol level, increasing triglyceride serum level, reducing glucose tolerance, raising blood pressure, and promoting clotting mechanisms. In this review we investigate the mechanism of the oral contraceptives and performed a risk assessment of every generation.
Export Options
About this article
Cite this article as:
Fazio Giovanni, Ferrara Filippo, Barbaro Gullotti Alessandro Giuseppe, Ferrro Giovanni, Novo Giuseppina and Novo Salvatore, Protrhombotic Effects of Contraceptives, Current Pharmaceutical Design 2010; 16 (31) . https://dx.doi.org/10.2174/138161210793563374
DOI https://dx.doi.org/10.2174/138161210793563374 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Fluctuations of Melatonin and Copeptin Levels in Blood Serum During Surgical Stress Regarding the Pediatric Population
Current Pediatric Reviews Phosphodiesterase 3 (PDE3): Structure, Localization and Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Serum Creatinine vs. Albuminuria as Biomarkers for the Estimation of Cardiovascular Risk
Current Vascular Pharmacology Cell Life Versus Cell Longevity: The Mysteries Surrounding the NAD+ Precursor Nicotinamide
Current Medicinal Chemistry TSH Variations in Chronic Heart Failure Outpatients: Clinical Correlates and Outcomes
Endocrine, Metabolic & Immune Disorders - Drug Targets Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia
Current Pharmaceutical Design Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Structure, Function and Biological Relevance of Prolyl Oligopeptidase
Current Protein & Peptide Science Neuroprotection and Sex Steroid Hormones: Evidence of Estradiol- Mediated Protection in Hypertensive Encephalopathy
Mini-Reviews in Medicinal Chemistry Serum Levels of Fibroblast Growth Factor 23 in People Living with HIV
Current HIV Research Measuring the Burden of Disease in the United Arab Emirates, 1990 – 2019: A Road to Future
New Emirates Medical Journal Experimental Models of Abdominal Aortic Aneurysms: An Overview
Current Pharmaceutical Design Drugs for AIDS
Mini-Reviews in Medicinal Chemistry Nicotine Addiction and Coronary Artery Disease: Impact of Cessation Interventions
Current Pharmaceutical Design Editorial [Hot topic: Crucial Role of Redox Signaling in the Regulation of Heart Health (Guest Editor: Dipak K. Das)]
Current Cardiology Reviews Proteomic Analysis of Liver Diseases: Molecular Mechanisms and Biomarker Discovery
Mini-Reviews in Medicinal Chemistry Editorial (Hot Topic: Vitamin D Deficiency and Critical Illness)
Inflammation & Allergy - Drug Targets (Discontinued) New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews Toll-Like Receptors and Human Disease: Lessons from Single Nucleotide Polymorphisms
Current Genomics Adipokines, Metabolism and the Immune Response in the Regulation of Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents